NEUROPATHIX
DEAD

Serial Number

90069642

Owner

Kannalife, Inc.

Filing Date

Jul 23, 2020

Add to watchlist:

No watchlists yet
View on USPTO

NEUROPATHIX Trademark

Serial Number: 90069642

NEUROPATHIX is a trademark filed by Kannalife, Inc. on July 23, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Kannalife, Inc. (3 trademarks)

3805 Old Easton Road
Doylestown, PA 18902

Entity Type: 03

Trademark Details

Filing Date

July 23, 2020

Registration Date

Not Registered

Goods & Services

Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparation for skin care; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for skin wounds; Pharmaceutical preparations for the prevention of osteoporosis; Pharmaceutical preparations for the prevention of chronic and neuropathic pain; Pharmaceutical preparations for the treatment and prevention of chronic and neuropathic pain; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of chronic and neuropathic pain; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for treating respiratory diseases; Pharmaceutical products for treating respiratory diseases and asthma; Anti-epileptic pharmaceutical preparations; Balms for pharmaceutical purposes; Digestives for pharmaceutical purposes; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Plant extracts for pharmaceutical purposes; Plant extracts for medical, veterinary and pharmaceutical purposes; Therapeutic pharmaceutical for the treatment of chronic and neuropathic pain

Pharmaceutical drug development services; Development of pharmaceutical preparations and medicines; Research and development in the pharmaceutical and biotechnology fields; Research in the field of chronic and neuropathic pain

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Mar 1, 2022 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Mar 1, 2022 ABN2
NOTIFICATION OF FINAL REFUSAL EMAILED
Aug 12, 2021 GNFN
FINAL REFUSAL E-MAILED
Aug 12, 2021 GNFR
FINAL REFUSAL WRITTEN
Aug 12, 2021 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 15, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 15, 2021 CRFA
ASSIGNED TO LIE
Jul 9, 2021 ALIE
NOTICE OF REVIVAL - E-MAILED
May 26, 2021 NREV
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 25, 2021 TROA
PETITION TO REVIVE-GRANTED
May 25, 2021 PETG
TEAS PETITION TO REVIVE RECEIVED
May 25, 2021 PROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 23, 2020 GNRN
NON-FINAL ACTION E-MAILED
Nov 23, 2020 GNRT
NON-FINAL ACTION WRITTEN
Nov 23, 2020 CNRT
ASSIGNED TO EXAMINER
Nov 12, 2020 DOCK
ASSIGNED TO EXAMINER
Nov 9, 2020 DOCK
ASSIGNED TO EXAMINER
Nov 9, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 21, 2020 NWOS
NEW APPLICATION ENTERED
Jul 27, 2020 NWAP